Developer docs
API playgroundTry for free, no card

Search company profiles

EMD Millipore

Full company profile

uuid000uoov

Namestring
EMD Millipore
Legal namestring
EMD Millipore (operating as part of MilliporeSigma, a division of Merck KGaA)
Company typeenum
Private
Founded yearint
2015
Descriptiontext

EMD Millipore operates the Life Science business of Merck KGaA under the MilliporeSigma brand, headquartered in Billerica, Massachusetts, with 10,000+ employees and a global footprint. The company sells a broad portfolio of over 300,000 products and services spanning filtration, water purification, cell culture, protein biology, molecular biology, analytical chemistry, and contract manufacturing and testing. Its offering is organized into six sub-brands — Millipore® (pharma and biopharma products and CTDMO services), Sigma-Aldrich® (lab and production materials), SAFC® (pharma raw materials), Supelco® (analytical products), Milli-Q® (lab water systems), and BioReliance® (contract testing) — covering the full workflow from research through commercial manufacturing.

Revenue is generated through product sales (consumables, reagents, instruments, and water systems priced per unit with volume discounts), contract manufacturing and testing services for pharmaceutical and biopharmaceutical customers, custom synthesis (oligos, peptides, siRNA), and IVD development and manufacturing. Go-to-market is sales-led, combining a global direct sales force for enterprise biopharma accounts, inside sales, the sigmaaldrich.com e-commerce platform for transactional SMB and academic buyers, and the MPartner digital marketplace for custom enterprise orders. Customer segments include pharmaceutical and biopharmaceutical companies, research institutions and academia, industrial and quality control labs, and healthcare and diagnostics providers.

The business was formed through the 2015 merger of Millipore and Sigma-Aldrich under Merck KGaA, and continues to invest in integrated service lines for monoclonal antibodies and mRNA development and manufacturing. In 2026 the company joined an MIT-led NIIMBL-funded consortium with Landmark Bio and Virica Biotech to improve AAV vector production for gene therapy, signalling continued expansion into emerging biopharma modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersBillerica, United States
HQ citystring
Billerica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
life science products, biopharmaceutical manufacturing services, lab water purification, analytical chemistry reagents, filtration consumables
Industry4 codes
1Gene Therapy (Viral Vector/Plasmid) CDMO
CodeHLAGABAEPrimaryYes
2mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
CodeHLAGAGACPrimaryNo
3Clinical Trial Material (CTM) Manufacturing & Supply CDMO
CodeHLAGABAKPrimaryNo
4Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
CodeHLAGAGAIPrimaryNo
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Laboratory Analytical Instruments3826
Product category
Life Science Tools and Biopharmaceutical Manufacturing Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Life Science Products
TypeOne Time License
Description

Sale of broad portfolio of research chemicals, biochemicals, reagents, labware, filtration products, water purification systems and consumables

sigmaaldrich.com
2Contract Manufacturing
TypeProfessional Services
Description

Contract manufacturing services for pharmaceutical and biopharmaceutical companies including mAbs and mRNA development and manufacturing

sigmaaldrich.com
3Contract Testing Services
TypeProfessional Services
Description

BioReliance contract testing services for pharmaceutical quality control and regulatory compliance

sigmaaldrich.com
4Custom Products
TypeProfessional Services
Description

Custom synthesis services including DNA oligos, RNA, siRNA, and custom peptides

sigmaaldrich.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Standard catalog products with volume discounts
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products like certified reference materials, solvents, and reagents are priced per unit with promotional discounts (e.g., 10-12% off on select items)

sigmaaldrich.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Millipore®
Description

Expert Pharma / BioPharma Products & CTDMO Services

sigmaaldrich.com
+5 more records
Core offering1 text field

EMD Millipore (MilliporeSigma) supplies a broad portfolio of life science products and services for pharmaceutical development and manufacturing, including filtration consumables, lab water purification systems, cell culture media and reagents, protein and molecular biology reagents, analytical chemistry standards, and CTDMO (contract testing, development, and manufacturing) services for mAbs and mRNA biotherapeutics. The company also offers certified reference materials, custom synthesis (DNA/RNA oligos, peptides), IVD development services, and digital life science platforms sold through six sub-brands (Millipore, Sigma-Aldrich, SAFC, Supelco, Milli-Q, BioReliance).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EMD Millipore, operating as MilliporeSigma under parent company Merck KGaA, is a diversified life science company offering a broad portfolio of products and services for pharmaceutical development and manufacturing. The company operates through six primary sub-brands: Millipore® (Pharma/BioPharma products and CTDMO services), Sigma-Aldrich® (Lab and production materials), SAFC® (Pharma raw material solutions), Supelco® (Analytical products), Milli-Q® (Lab water solutions), and BioReliance® (Contract testing services). The portfolio spans analytical chemistry, cell culture, filtration, molecular biology, protein biology, mAbs and mRNA development and manufacturing, and water purification. Services include contract manufacturing, contract testing, custom products, digital solutions, and IVD development. The company also participates in public-private partnerships for biopharmaceutical innovation, including NIIMBL consortia for viral vector production improvements.

Product and service13 records
1Millipore Pharma and BioPharma Products and CTDMO Services
CategoryPharma and Biopharma Products and Services
Description

Expert pharma and biopharma products and CTDMO (Contract Testing, Development, and Manufacturing Organization) services for the biopharmaceutical industry.

2Sigma-Aldrich Lab and Production Materials
CategoryLab and Production Materials
Description

Lab and production materials including chemicals, reagents, certified reference materials, and lab essentials for research and industrial applications.

3SAFC Pharma and Biopharma Raw Material Solutions
CategoryPharma Raw Materials
Description

Pharma and biopharma raw material solutions providing critical ingredients and materials for pharmaceutical manufacturing.

4Supelco Analytical Products
CategoryAnalytical Products
Description

Analytical products including chromatography columns, stationary phases, and analytical reagents for laboratory testing and quality control.

5Milli-Q Lab Water Solutions
CategoryLab Water Purification
Description

Lab water solutions including water purification systems, consumables, and services for producing ultra-pure water in laboratory environments, with the Milli-Q CLX 8Series addressing clinical lab water needs.

6BioReliance Contract Testing Services
CategoryContract Testing Services
Description

Contract testing services providing biosafety testing, characterization, and regulatory compliance testing for biopharmaceutical products.

7mAbs Development and Manufacturing Services
CategoryBiologics CDMO Services
Description

Integrated monoclonal antibody development and manufacturing services from cell line development to final drug substance.

8mRNA Development and Manufacturing Services
CategoryNucleic Acid CDMO Services
Description

End-to-end mRNA development and manufacturing services including process development, GMP production, and analytics.

9Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

Custom manufacturing services for pharmaceutical intermediates, APIs, and complex molecules under GMP conditions.

10Contract Testing Services
CategoryContract Testing Services
Description

Comprehensive testing services including biosafety testing, impurity profiling, and regulatory compliance testing.

11Custom Products Services
CategoryCustom Synthesis Services
Description

Custom synthesis, custom peptides, custom oligos, and made-to-order chemical products.

12IVD Development and Manufacturing Services
CategoryIVD Development Services
Description

In vitro diagnostic product development and manufacturing services for regulatory approval.

13ReCycler Solvent Systems
CategorySustainability Services
Description

Solvent recycling and returnable container systems that reduce packaging waste and eliminate hazardous disposal costs.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

MIT-led consortium with EMD Millipore, Landmark Bio, and Virica Biotech focused on improving adeno-associated viral vector production for gene therapy. The project aims to reduce empty viral capsids in collaboration with NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Part of MIT-led consortium working on adeno-associated viral vector production for gene therapy. Landmark Bio contributes to the effort to reduce empty viral capsids in partnership with EMD Millipore.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Part of MIT-led consortium focused on improving adeno-associated viral vector production. Virica Biotech collaborates with EMD Millipore, Landmark Bio, and MIT to advance gene therapy manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

NIIMBL is a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation. EMD Millipore is part of an MIT-led consortium funded by NIIMBL to support domestic viral vector production for gene therapy.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Life science research and clinical diagnostics company offering reagents, instruments, and process chromatography. Competes in protein biology, molecular biology, and bioprocess chromatography.

TypeDirect peer
Description

World's largest contract development and manufacturing organization (CDMO) for biologics, cell and gene therapies, and mRNA. Direct competitor in mAbs, mRNA, and gene therapy CDMO services.

TypeEmerging player
Description

Specialty bioprocessing company focused on filtration, chromatography, and process analytics. Emerging direct competitor in bioprocess filtration and CDMO-adjacent consumables.

TypeDirect peer
Description

Leading bioprocessing and fermentation supplier with strong filtration and single-use technologies for biopharma manufacturing. Direct peer in upstream/downstream bioprocessing and CDMO enablement.

TypeDirect peer
Description

Specialty analytical instruments and chromatography consumables provider. Competes with Supelco and analytical chemistry product lines in LC, MS, and chromatography.

TypeBroad incumbent
Description

Global contract testing services group offering bioanalytical, pharmaceutical, and microbiological testing. Overlaps with BioReliance contract testing and industrial microbiology QC services.

TypeDirect peer
Description

Analytical instruments and life science consumables provider competing in chromatography, mass spectrometry, and lab chemicals/reagents within EMD Millipore's analytical chemistry portfolio.

TypeDirect peer
Description

Contract research organization providing preclinical, biosafety, and manufacturing support services. Overlaps with BioReliance contract testing and biopharma quality control offerings.

TypeDirect peer
Description

Diversified life science conglomerate owning Cytiva (bioprocessing) and Beckman Coulter (life sciences). Competes directly in bioprocessing consumables, filtration, and CDMO-adjacent services.

TypeDirect peer
Description

Largest life science tools and CDMO player globally, offering analytical instruments, reagents, bioprocessing products, and contract manufacturing services (Patheon). Direct competitor across filtration, reagents, analytical, and CDMO.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EMD Millipore

Life Science Tools and Biopharmaceutical Manufacturing Servicesemdmillipore.com

What EMD Millipore does

EMD Millipore operates the Life Science business of Merck KGaA under the MilliporeSigma brand, headquartered in Billerica, Massachusetts, with 10,000+ employees and a global footprint. The company sells a broad portfolio of over 300,000 products and services spanning filtration, water purification, cell culture, protein biology, molecular biology, analytical chemistry, and contract manufacturing and testing. Its offering is organized into six sub-brands — Millipore® (pharma and biopharma products and CTDMO services), Sigma-Aldrich® (lab and production materials), SAFC® (pharma raw materials), Supelco® (analytical products), Milli-Q® (lab water systems), and BioReliance® (contract testing) — covering the full workflow from research through commercial manufacturing.

Revenue is generated through product sales (consumables, reagents, instruments, and water systems priced per unit with volume discounts), contract manufacturing and testing services for pharmaceutical and biopharmaceutical customers, custom synthesis (oligos, peptides, siRNA), and IVD development and manufacturing. Go-to-market is sales-led, combining a global direct sales force for enterprise biopharma accounts, inside sales, the sigmaaldrich.com e-commerce platform for transactional SMB and academic buyers, and the MPartner digital marketplace for custom enterprise orders. Customer segments include pharmaceutical and biopharmaceutical companies, research institutions and academia, industrial and quality control labs, and healthcare and diagnostics providers.

The business was formed through the 2015 merger of Millipore and Sigma-Aldrich under Merck KGaA, and continues to invest in integrated service lines for monoclonal antibodies and mRNA development and manufacturing. In 2026 the company joined an MIT-led NIIMBL-funded consortium with Landmark Bio and Virica Biotech to improve AAV vector production for gene therapy, signalling continued expansion into emerging biopharma modalities.

EMD Millipore firmographics

Firmographics
Name
EMD Millipore
Legal name
EMD Millipore (operating as part of MilliporeSigma, a division of Merck KGaA)
Website
https://emdmillipore.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

EMD Millipore industry classification

Industry
Product category
Life Science Tools and Biopharmaceutical Manufacturing Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)
akta.pro primary industry
Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
akta.pro secondary industries
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)

Keywords

  • Life science products
  • Biopharmaceutical manufacturing services
  • Lab water purification
  • Analytical chemistry reagents
  • Filtration consumables

Where EMD Millipore is headquartered

Location

Headquarters

HQ city
Billerica
HQ country
United States
HQ region
North America

Markets served

EMD Millipore business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Life Science Products: Sale of broad portfolio of research chemicals, biochemicals, reagents, labware, filtration products, water purification systems and consumables
  2. Contract Manufacturing: Contract manufacturing services for pharmaceutical and biopharmaceutical companies including mAbs and mRNA development and manufacturing
  3. Contract Testing Services: BioReliance contract testing services for pharmaceutical quality control and regulatory compliance
  4. Custom Products: Custom synthesis services including DNA oligos, RNA, siRNA, and custom peptides

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard catalog products with volume discounts

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

EMD Millipore product offering

Product offering

Core offering

EMD Millipore (MilliporeSigma) supplies a broad portfolio of life science products and services for pharmaceutical development and manufacturing, including filtration consumables, lab water purification systems, cell culture media and reagents, protein and molecular biology reagents, analytical chemistry standards, and CTDMO (contract testing, development, and manufacturing) services for mAbs and mRNA biotherapeutics. The company also offers certified reference materials, custom synthesis (DNA/RNA oligos, peptides), IVD development services, and digital life science platforms sold through six sub-brands (Millipore, Sigma-Aldrich, SAFC, Supelco, Milli-Q, BioReliance).

Product overview

EMD Millipore, operating as MilliporeSigma under parent company Merck KGaA, is a diversified life science company offering a broad portfolio of products and services for pharmaceutical development and manufacturing. The company operates through six primary sub-brands: Millipore® (Pharma/BioPharma products and CTDMO services), Sigma-Aldrich® (Lab and production materials), SAFC® (Pharma raw material solutions), Supelco® (Analytical products), Milli-Q® (Lab water solutions), and BioReliance® (Contract testing services). The portfolio spans analytical chemistry, cell culture, filtration, molecular biology, protein biology, mAbs and mRNA development and manufacturing, and water purification. Services include contract manufacturing, contract testing, custom products, digital solutions, and IVD development. The company also participates in public-private partnerships for biopharmaceutical innovation, including NIIMBL consortia for viral vector production improvements.

Differentiator

Problem solved

Functional benefit

Brands

  • Millipore®: Expert Pharma / BioPharma Products & CTDMO Services
  • Sigma-Aldrich®
  • SAFC®
  • Supelco®
  • Milli-Q®
  • BioReliance®

Products and services

  • Millipore Pharma and BioPharma Products and CTDMO Services Expert pharma and biopharma products and CTDMO (Contract Testing, Development, and Manufacturing Organization) services for the biopharmaceutical industry.
  • Sigma-Aldrich Lab and Production Materials Lab and production materials including chemicals, reagents, certified reference materials, and lab essentials for research and industrial applications.
  • SAFC Pharma and Biopharma Raw Material Solutions Pharma and biopharma raw material solutions providing critical ingredients and materials for pharmaceutical manufacturing.
  • Supelco Analytical Products Analytical products including chromatography columns, stationary phases, and analytical reagents for laboratory testing and quality control.
  • Milli-Q Lab Water Solutions Lab water solutions including water purification systems, consumables, and services for producing ultra-pure water in laboratory environments, with the Milli-Q CLX 8Series addressing clinical lab water needs.
  • BioReliance Contract Testing Services Contract testing services providing biosafety testing, characterization, and regulatory compliance testing for biopharmaceutical products.
  • mAbs Development and Manufacturing Services Integrated monoclonal antibody development and manufacturing services from cell line development to final drug substance.
  • mRNA Development and Manufacturing Services End-to-end mRNA development and manufacturing services including process development, GMP production, and analytics.
  • Contract Manufacturing Services Custom manufacturing services for pharmaceutical intermediates, APIs, and complex molecules under GMP conditions.
  • Contract Testing Services Comprehensive testing services including biosafety testing, impurity profiling, and regulatory compliance testing.
  • Custom Products Services Custom synthesis, custom peptides, custom oligos, and made-to-order chemical products.
  • IVD Development and Manufacturing Services In vitro diagnostic product development and manufacturing services for regulatory approval.
  • ReCycler Solvent Systems Solvent recycling and returnable container systems that reduce packaging waste and eliminate hazardous disposal costs.

Companies that use EMD Millipore

Customer profile

Segments4 records

Ideal customer profiles4 records

EMD Millipore technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

EMD Millipore partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Massachusetts Institute of Technology (MIT)coreStrategic or Co-development Partner · 3 June 2026MIT-led consortium with EMD Millipore, Landmark Bio, and Virica Biotech focused on improving adeno-associated viral vector production for gene therapy. The project aims to reduce empty viral capsids in collaboration with NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals).
  • Landmark BiocoreStrategic or Co-development Partner · 3 June 2026Part of MIT-led consortium working on adeno-associated viral vector production for gene therapy. Landmark Bio contributes to the effort to reduce empty viral capsids in partnership with EMD Millipore.
  • Virica BiotechcoreStrategic or Co-development Partner · 3 June 2026Part of MIT-led consortium focused on improving adeno-associated viral vector production. Virica Biotech collaborates with EMD Millipore, Landmark Bio, and MIT to advance gene therapy manufacturing.
  • NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals)coreStrategic or Co-development Partner · 3 June 2026NIIMBL is a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation. EMD Millipore is part of an MIT-led consortium funded by NIIMBL to support domestic viral vector production for gene therapy.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

EMD Millipore competitors and assessment

Company assessment

Direct peers

  • Bio-Rad Laboratories: Life science research and clinical diagnostics company offering reagents, instruments, and process chromatography. Competes in protein biology, molecular biology, and bioprocess chromatography.
  • Lonza Group: World's largest contract development and manufacturing organization (CDMO) for biologics, cell and gene therapies, and mRNA. Direct competitor in mAbs, mRNA, and gene therapy CDMO services.
  • Sartorius: Leading bioprocessing and fermentation supplier with strong filtration and single-use technologies for biopharma manufacturing. Direct peer in upstream/downstream bioprocessing and CDMO enablement.
  • Waters Corporation: Specialty analytical instruments and chromatography consumables provider. Competes with Supelco and analytical chemistry product lines in LC, MS, and chromatography.
  • Agilent Technologies: Analytical instruments and life science consumables provider competing in chromatography, mass spectrometry, and lab chemicals/reagents within EMD Millipore's analytical chemistry portfolio.
  • Charles River Laboratories: Contract research organization providing preclinical, biosafety, and manufacturing support services. Overlaps with BioReliance contract testing and biopharma quality control offerings.
  • Danaher (Cytiva): Diversified life science conglomerate owning Cytiva (bioprocessing) and Beckman Coulter (life sciences). Competes directly in bioprocessing consumables, filtration, and CDMO-adjacent services.
  • Thermo Fisher Scientific: Largest life science tools and CDMO player globally, offering analytical instruments, reagents, bioprocessing products, and contract manufacturing services (Patheon). Direct competitor across filtration, reagents, analytical, and CDMO.

Emerging players

  • Repligen Corporation: Specialty bioprocessing company focused on filtration, chromatography, and process analytics. Emerging direct competitor in bioprocess filtration and CDMO-adjacent consumables.

Broad incumbents

  • Eurofins Scientific: Global contract testing services group offering bioanalytical, pharmaceutical, and microbiological testing. Overlaps with BioReliance contract testing and industrial microbiology QC services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

EMD Millipore social profiles

Digital presence

EMD Millipore financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EMD Millipore leadership team

Management profile

Number of profiles

Profiles1 record

EMD Millipore funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EMD Millipore M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMD Millipore

What does EMD Millipore do?

EMD Millipore (MilliporeSigma) supplies a broad portfolio of life science products and services for pharmaceutical development and manufacturing, including filtration consumables, lab water purification systems, cell culture media and reagents, protein and molecular biology reagents, analytical chemistry standards, and CTDMO (contract testing, development, and manufacturing) services for mAbs and mRNA biotherapeutics. The company also offers certified reference materials, custom synthesis (DNA/RNA oligos, peptides), IVD development services, and digital life science platforms sold through six sub-brands (Millipore, Sigma-Aldrich, SAFC, Supelco, Milli-Q, BioReliance).

Is EMD Millipore a public or private company?

EMD Millipore is a private company. It is classified as corporate owned and is currently operating.

When was EMD Millipore founded?

EMD Millipore was founded in 2015. It employs 5,001 to 10,000 people.

Where is EMD Millipore based?

EMD Millipore is headquartered in Billerica, United States, in the North America region.

How does EMD Millipore make money?

Four revenue lines are on record. Life Science Products are the primary driver. The others are contract Manufacturing, contract Testing Services and custom Products.

Who are EMD Millipore's main competitors?

Direct peers on record are Bio-Rad Laboratories, Lonza Group, Sartorius, Waters Corporation, Agilent Technologies, Charles River Laboratories, Danaher (Cytiva) and Thermo Fisher Scientific. Repligen Corporation is listed as an emerging player. Eurofins Scientific is listed as a broad incumbent.

Does EMD Millipore have an API?

No public API is recorded for EMD Millipore.

What industry is EMD Millipore in?

EMD Millipore's product category is Life Science Tools and Biopharmaceutical Manufacturing Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 3254 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsNIIMBL to Support Vector Production and AI-Ready Training ProjectsNIIMBL, a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation, announced 39 funding awards to support domestic production and talent development. Several projects focus on improving adeno-associated viral vector production for gene therapy, including work by Michigan Technological University, North Carolina State, and an MIT-led consortium with EMD Millipore, Landmark Bio, and Virica Biotech to reduce empty viral capsids. Additional initiatives include workforce training programs such as Texas A&M University's NeuroPipes program for neurodiverse adults and the Wistar Institute's BioPATH national consortium focused on biomanufacturing, AI, and automation.PR NewswireOutlook on the Binder Excipients Global Market to 2026 - by Product Type, Application and RegionResearch and Markets announced the addition of a global binder excipients market report, estimating the market reached US$1.33 billion in 2020 and projecting moderate growth through 2021-2026. Key growth drivers include an aging population, rising chronic diseases, drug patent expiries, nanotechnology advancements, and increasing demand for functionality excipients. The report identifies Colorcon, Croda International, EMD Millipore, Dow Chemical, FMC BioPolymer, Fuji Chemical Industry, and Ingredion as key players in the competitive landscape.PR Newswire2019 Hematology Analyzers & Reagents Market Drivers, Major Players And Restrain Report by TBRCThe Business Research Company released a 2019 market report on the hematology analyzers and reagents market, projecting growth from $3.19 billion in 2018 to $4.27 billion by 2022 at an annual rate exceeding 7.5%, driven by increasing global blood donations and demand from blood banks for screening and testing equipment. Product recalls of defective analyzers, such as Beckman Coulter Life Sciences' recall of its DxH800, DxH600, and DxH 900 hematology analyzers due to risks of inaccurate results, are identified as restraints on market growth. Major players in the market include Abbott, Bio-Rad Laboratories, Horiba, Siemens, and Sysmex, with companies increasingly investing in mergers and acquisitions activity, exemplified by Luminex Corporation's $75 million acquisition of EMD MilliporeSigma's flow cytometry portfolio in January 2019.PR NewswireEMD Millipore Introduces the Mobius® 2000 Liter Single-Use Bioreactor with Industry-leading Design for Ease-of-UseEMD Millipore introduced the Mobius 2000 liter single-use bioreactor, which joins its 3-2000 liter portfolio. The bioreactor features a pull-out drawer, self-deploying bag, and a 5:1 turndown ratio for flexible seeding and harvesting. It also includes an external SensorReady loop for process monitoring.Water OnlineEMD Millipore Introduces New High-Performance Water Purification Systems With 24/7 Real-Time Monitoring And Remote ControlEMD Millipore, the Life Science business of Merck KGaA, has introduced a new line of high-performance water purification systems (AFS 40E/80E/120E and 150E) designed for clinical laboratories. These systems utilize Elix electrodeionization and E.R.A technologies to ensure constant water quality while offering 24/7 real-time monitoring and remote control capabilities to maximize operational uptime.GlobeNewswireEMD Millipore and the Centre for Commercialization of Regenerative Medicine Collaborate to Optimize Conditions for Large-Scale Stem Cell CultivationEMD Millipore and the Centre for Commercialization of Regenerative Medicine announced a collaboration to develop optimized conditions for bioreactor-based stem cell cultivation. The project will create a proprietary monitoring and control methodology for EMD Millipore's Mobius CellReady bioreactor, delivering a commercially available kit. Work began on February 27, 2012.